Preliminary data show intracameral implant reduces IOP up to 9 months
SAN FRANCISCO — An intracameral travoprost implant reduced IOP for up to 9 months in preliminary results from a phase 1 study, according to a speaker here.
The open-label, proof-of-concept study included 20 subjects who received one of two formulations of OTX-TIC (travoprost implant, Ocular Therapeutix), administered via a single injection, or travoprost eye drops.
IOP lowering in both implant cohorts was on par with the drop cohort, Michael H. Goldstein, MD, MBA, said at Glaucoma 360: New Horizons Forum. However, patients in both OTX-TIC cohorts experienced the lowering effect for much longer than anticipated.
“We were targeting 4 months, but what we found is that we are actually seeing much longer drug duration than we were expecting,” Goldstein said.
All patients in both cohorts were evaluated at 6 months and continued to experience the IOP reduction, while some early trial patients have seen IOP reduction up to 9 months. The lead patient’s results have lasted until 18 months.
The insert itself is designed to be bioabsorbable.
“We’ve seen all of the inserts go away between 5 to 7 months,” Goldstein said.
Adverse events included some inflammation, which was treated with steroids or NSAIDS, three cases of peripheral anterior synechiae and one case of cornea edema. Corneal health has not been negatively affected, with endothelial cell counts and pachymetry assessments indicating no changes from baseline.
“We are seeing a clinically meaningful decrease in IOP with a single insert,” Goldstein said. – by Rebecca L. Forand
Goldstein M. Transforming glaucoma care with drug delivery: Leveraging a novel technology platform. Presented at Glaucoma 360: New Horizons Forum; Feb. 7, 2020; San Francisco.
Disclosure: Goldstein reports he is an employee of Ocular Therapeutix.